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The two-compartment model of Rowland et al., (2) has been extended by replacing first order 
elimination with Michaelis-Menten elimination kinetics. All of  the equations for steady-state 
concentrations and clearances for zero order (constant rate) input orally (into compartment / /2)  
and intravenously (into compartment//I) are derived and reported. The steady-state concentration 
in compartment//1, following intravenous administration, is shown to be a nonlinear function of 
maximal velocity of metabolism, V~, the Michaelis constant, Kin, and liver blood flow, Q; and, 
following oral administration is dependent only upon Vm and K~, and is independent of  Q. 
However, oral bioavailability is a function of V~, Km, and Q. The model allows physiologic 
pharmaeokinetie interpretation of  both linear and nonlinear data; and, together with simple 
modification of  the model, can explain mueh observed pharmaeokinetic data to date particularly 
for first-pass drugs. Future articles in the series will be concerned with single doses, evaluation of 
literature data in terms of  the model, application of the theory in toxicology and in clinical 
pharmaeokinetics and therapeutics. 
KEY WORDS: pharmacokinetic theory; venous equilibration ("well-stirred") model; compart- 
ment model; linear pharmacokinetics; nonlinear pharmacokinetics; bioavailability; intrinsic 
clearance; liver blood flow; clearance. 
I N T R O D U C T I O N  
Two types o f  well-defined quantitative models  have been developed 
which a t tempt  to describe the elimination o f  flowing substrates in the intact 
liver. One of  these models  has been termed the venous equil ibration or 
"well-st irred" model  (1-13) and has been developed mainly by Rowland  
(1, 2, l l, 12), Pang and Rowland  (5-7),  and Wilkinson (3, 4, 8). The other  
has been termed the sinusoidal perfusion or  "paral le l - tube"  model  (14-31) 
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and has been mainly developed by Bass et al., (14, 16, 18-23, 25-27) and 
Keiding et aL, (15, 17, 24, 28, 29). 
The principal parts of the venous equilibration or "well-stirred" model 
were developed from the model of an isolated perfused organ system 
containing a reservoir and an eliminating organ and from the two-compart- 
ment open model with elimination from the peripheral compartment as 
depicted in Scheme I, but using the symbolism later used in this article 
rather than that of Rowland et al. (2). Hence, in reality there are really 
three models, two of which are the so-called "well-stirred" model and the 
specific compartment model of Scheme I and these two are equivalent 
mathematically. In the "well-stirred" model one measures concentrations 
in the reservoir or compartment #1 of Scheme I, following either oral 
administration into compartment #2, or intravenous administration into 
compartment # 1. 
Tucker (32) published a hydrodynamic analogue to the model of 
Scheme I and showed that all of the expectations of modern physiological 
pharmacokinetics may be derived from the analogue to the two-compart- 
ment model providing first order kinetics are obeyed. 
We have extended the model of Rowland et al. (2) by replacing first 
order elimination by Michaelis-Menten elimination. We treat the steady- 
state in this article; a future article will consider single doses of drug given 
intravenously and orally. In subsequent articles we will show that consider- 
able literature data on first-pass drugs may be explained by the simple 
models of Schemes I and II or obvious extensions of them. 
The primary purpose of this article was to derive nonlinear equations 
involving Michaelis-Menten elimination to use in interpretation of literature 
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data and new data available to the authors. With the exception of one article 
(25) all the other articles involving the sinusoidal perfusion model (14- 
24, 26-29) apply to the steady-state. Hence, a secondary purpose of this 
article was to derive equations extending the venous equilibration model 
(5-7) to the steady-state so comparisons could be made between the venous 
equilibration model and the sinusoidal perfusion model with respect to the 
steady-state. However, the latter comparisons are not made in this article. 
THEORY 
Compartment Model 
The model is a modification of the "upside-down" two-compartment 
open model of  Rowland et aL (2), altered to include Michaelis-Menten 
elimination kinetics. In this article, we discuss only the steady-state situation 
following administration of the drug at a zero order (constant) rate, Ro, 
either orally or intravenously, The equations developed assume complete 
availability of drug to the liver (i.e., FL = 1); if not, then FL would be less 
than unity and would multiply Ro when oral administration was considered. 
Since we are considering the steady-state then any number of other "tissue" 
or other compartments could be connected to compartments #1 and # 2  
by first order rate constants and the kinetic situation would not be changed. 
It is assumed that whole blood concentrations of  drug are measured in 
compartment # 1, hence the equations developed contain the liver blood 
flow, designated as Q. If plasma concentrations were measured in compart- 
ment CA1, then the Q in this article would represent rQ where r is the 
blood/plasma concentration ratio of drug. The model of Scheme I considers 
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only the formation of a single metabolite according to Micheaelis-Menten 
kinetics with maximal velocity, Vm, and Michaelis constant, Kin. However, 
in the general model (not shown) there may be parallel Michaelis-Menten 
and /o r  first order paths and parallel elimination of unchanged drug accord- 
ing to first order kinetics. In the latter case equations developed later would 
have to be modified. 
Symbolism 
Note that "1" refers to compartment #1 ,  ss refers to steady-state, po 
refers to oral administration, IV refers to intravenous administration, z 
refers to zero order (constant rate) input. "Concentrat ion" refers to whole 
blood concentration when Q is actually liver blood flow, and to plasma 
concentration when Q is equal to rQ(1). Symbols are arranged alphabeti- 
cally. 
(AUC 0-oe)w: The area under the concentration-time curve from zero to 
infinite time after a single dose of drug given intravenously. 
(AUC 0-oe)vo: The area under the concentration-time curve from zero to 
infinite time after a single dose of drug given orally. 
c i V z  . ~,s- The measurable constant steady-state concentration in 
compartment # 1 during an intravenous infusion at the zero 
order rate, Ro, to steady-state. 
C p o z  . ~ss. The measurable constant steady-state concentration in 
compartment #1 during an oral input at the zero order 
rate, Ro, to steady-state. 
C POZ . ~s,. The average steady-state concentration in compartment # 1 
after oral administration during a dosage interval, defined 
as the area under the concentration-time curve divided by 
the dosage interval. 
c i V z  f ~ p o z .  2s~ and ,--2ss. Corresponding concentrations for compartment #2.  
Ci: The input concentration of drug to the liver compartment 
r~poz for intravenous or oral equivalent to Cfs v or ~1,~ 
administration, respectively. 
Co: The output concentration of  drug from the liver compart- 
c~1Vz rP~ for steady-state ment--equivalent  to , 2s~ or ,~2s, 
intraveneous or oral administration, respectively. 
CLH: The systemic or hepatic clearance = QCLd (Q + CL~). 
CLi: The intrinsic clearance of total drug for the model of 
Scheme II. Intrinsic clearance of free drug is CLJfu. 
C ~ "  l V z f .  ~ s ,  . The steady-state hepatic or systemic clearance of free drug 
for the model of Scheme II. 
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The steady-state oral clearance of free drug for the model 
of Scheme II. 
Equivalent to CLi. 
The renal clearance of unchanged drug. 
The steady-state clearance of total drug for oral administra- 
tion (Scheme II) at rate Ro. 
The steady-state clearance of total drug for intravenous 
administration (Scheme II) at rate Ro. 
The dose of drug given intravenously. 
The dose of drug given orally. 
The intrinsic extraction ratio of the drug at a specified liver 
blood flow, Q (defined by Eq. 47). 
The steady-state hepatic extraction ratio of the drug 
(defined by Eq. 46) at a specified liver blood flow. 
The intrinsic bioavailability of the drug according to the 
model of Schemes I and II at a specified liver blood flow 
(see Eq. 44). 
Bioavailability of drug to the liver. 
The bioavailability of the drug under steady-state condi- 
tions for the model of Scheme II (defined by Eq. 41). 
The fraction of drug free (unbound) in blood. Equations 
derived assume linear plasma protein and tissue binding. 
First order distribution rate constants (see Schemes I and 
II). 
Rate constant for renal excretion of unchanged drug. 
The first order elimination rate constant = Vm/V2Km when 
relating models of Schemes I and II. 
The Michaelis constant for the model of Scheme II, 
equivalent to the concentration, C2, when the rate of meta- 
bolism is equal to one-half of Vm. 
The whole blood/plasma drug concentration ratio. 
The liver blood flow (vol/time) if whole blood drug con- 
centration is measured or rQH if plasma is measured, where 
OH is true hepatic liver blood flow; in Schemes I and II 
Q = Vlkl2 = V2k21. 
The constant (zero order) input rate. 
The velocity of metabolism at steady-state. 
The maximal velocity of metabolism (Scheme II). 
The volume of compartment # 1 in the models of Schemes 
I and II. In applications this is an apparent volume. 
The volume of compartment #2 in the models of Schemes 
I and II. Note that V2=(k12/kz1)V1. 
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First Order Model of Scheme I 
Equal intercompartmental clearances (equivalent to our V~kx2 = V2k21) 
were assumed by Dedrick and Forrester (33), Perrier and Gibaldi (34), and 
Strong et al. (35). The model of Dedrick and Forrester (33) is identical with 
the model of Scheme II. The derivations to follow clearly show that to 
obtain the accepted expressions for the systemic and oral clearances (2,3) 
using the classical method of writing the differential equations (shown 
below), one must assume that the intercompartmental clearances in the 
model of Schemes I and II are equal. 
Intravenous Administration to Steady-State 
The differential equations are as follows. 
( dr~ iVz\ 
T }  / _ v c - w  ~_ V~k~c"w V 1  ~ ' l s s  = R o  V t n . 1 2 , . ~ l s  s - ~-2ss = 0  (1) 
V 2 ( * @ )  /. p t w _  V2k21f, lv~ v l.- f,f_v~ 
= V l ~ ' 1 2 " ~ l s s  " ~ 2 s s  - -  " 2 n ' e l ' ~ 2 s s  = 0  (2) 
From Eq. (1) we get: 
IZ  1.- 1 " ~ l V z  1,7 b- f .  I V z  Ro = 9 1~-12~.-- lss - -  v2~21"-~2ss (3) 
Substituting from Eq. (3) into Eq. (2) gives: 
(d 
r~ 1v~x 
T )  = v V t ~tvz V 2  '....2ss R o -  , 2n . e l 'C .~2s s  = 0  (4) 
Now, the intrinsic clearance of compartment #2  of the model of Scheme 
I is the product of the volume, V2, and the first order elimination rate 
constant, kel. Hence, from Eq. (4) we obtain Eq. (5): 
IZ  b" g '~IVz - -  [~1" f ~ l V z  (5) 
R o ~ v 2 n , e l ~ . ~ 2 s  s - ~.~x. , i~.2s s 
Solving for ,--2ssC'tvz in Eq. (3) we get: 
l V z  
r~wz Vlkl2Clss - Ro 
9 --2,, - (6) 
V2k21 
Substituting from Eq. (6) into Eq. (5) yields: 
( V ' k I 2 C I W -  R~ (7) 
Ro = CLi V2k21 / 
To obtain the accepted expression for hepatic clearance (2, 3, 5) from Eq. 
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(7) requires one to assume that: 
Q = Vlkl2 = V2k2, 
Substituting from Eq. (8) into Eq. (7) gives: 
Ro P [  ~ I V z  _ - -  QC,s ,  - R  e = CLi c~V~ = "-'~i'-~,~ 
Ro = CLi O 
Equation (9) may be rearranged to: 










-'-'lss = ~ p o z  = C L i  = Vekel 
"~-~ lss 
CLXV, Ro CLi QCLi ( 11 ) 
I ss f ,  l l V z  
" - ~ I s s  C L i  Q + C L i  
I + - -  Q 
which is the accepted hepatic clearance after intravenous administration. 
Oral Admin i s t ra t ion  to S teady-S ta te  
The differential equations are as follows. 
VI dCP~ _ V V  c~v ~ v v c~;oz= 0 (12) 
poz 
" { d C 2 s s ' ~  17 b p p o z  V2k21t~POZ V 2 k e l g ~ p o z  o (13) 
V 2 ~ T ) = R o + - - l , ~ . 1 2 " ~ ' l s s  ~,-~2ss ~-~2ss-- 
From Eq. (12) we get: 
k g .poz  V 2 k 2 1 ~ P O Z  (14) Vl 12 ~" 2ss "~-'2ss 
Substituting from Eq. (14) into Eq. (13) gives: 
Ro ~ll~ ~ p o ~ = ~ T r p o z  (15) = 1,2~el~_~2ss ~.~Lq~.~2s s 
To obtain the accepted clearance one has to assume that Eq. (8) applies. 
Substituting from Eq. (8) into Eq. (14) gives: 
Cpoz ~poz (16) lss ~-- "--'2ss 
Substituting from Eq. (16) into Eq. (15) gives: 
= r~t  r~po~ (17) Ro , ~ i ~  lss 
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Nonlinear Model of Scheme II 
Intravenous Administration to Steady-State 
The differential equations are as follows. 
IVz . / d C , s , \  
- -  V l k l 2 C l s  s ~- , 2 ~ , 2 1 ~ . . ~ 2 s s  = 0 (19) vl T)=Ro ,vz  ,vz 
/ dC wz\  v ,'~ wz I - - |  2ss = 1/', 1 ~ . 1 2 ~ J  l s  s - - b "  p l V z I f  lr f ~ l V z  " ml '~2ss  - -  0 (20) 
. ,  
From Eqs. (8) and (19) one obtains for across the liver: 
= c~rc~wz- rlVz~ (21) 
N o  ~ \ ~ - ~  lss  ".J2ss ] 
Substituting from Eqs. (8) and (21) into Eq. (20) yields Eq. (22). 
Wm ['~ l Vz 
~" 2ss 
Ro Km + r lvz  (22) 
"~ 2ss 
c~Wz in Eq. (22) yields Eq. (23). Solving for ~2ss 
CWZ KmRo (23) 
2s~-Vm_Ro 
Substituting from Eq. (23) into Eq. (21) gives Eq. (24). 
( , w  KmRo.~ (24) 
Ro=O C.~ Vm-Ro/ 
l.-, I Vz Solving for ,~ ,~s  in Eq. (24) yields Eq. (25). 
, ,~ = Ro + Ro (25) 
It should be noted that Eq. (22) through (25) require that V,, > Ro and are 
invalid when Ro >- V,,. 
Equation 25 is new and indicates that measurement of ,~vz, I ss S for four 
different Ro values would allow nonlinear estimation of the variables Q, 
Vm and Km with one degree of freedom remaining. If Q was measured 
independently, such as by indocyanine clearance or another method, then 
Vm and Km could be determined following two or three different infusions. 
Oral Administration to Steady-State 
The differential equations are: 
poz 
V I ~ T )  = - - V l n , 1 2 1 . ~ l s  s - -  , 2 n , 2 1 , . - , 2 s s  = 0  (26) 
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poz  . { d C ~ , , \  
v 2 ~ T ) = R o _ V 2 k 2 1 g ~ p o z . . . ~ _  l / b -  I '~P ~  ~ J 2 s s  ~ 9 l t ~ 1 2 x ' ~  l s s  
Equations 8 and 26 give Eq. (16), that is: 
C POZ _ poz  
l s s  - C 2 s s  
Hence it follows in the oral case that: 
C L p O Z _  r ~ t p o z  
2ss - -  ~ l - -~ l s s  
Equations 8, 16, and 27 give Eq. (29). 
V m [ - ~  poz  
12 - -  [ ~ l  poz  . f ~ p o z  
['~ poz  
K ~  + %-~lss 
Solving for ,~V~ in Eq. (29) yields Eq. (30). 
KmRo Ro [-~ poz  - -  
I poz  
" ~ *  Vm - R o  ~.JZ~lss 
From eqs. (29) and (30) it follows that: 
Vrn  ~ p ~  ,.-, 2ss  






Ro Vm V m - R o  _ _ =  c~rpoz (31) 
poz ~.-,lss - r,voz - Km 
~lxs gm + ~lxs 
As before, Eqs. (29-31) require that Vm > Ro and are invalid if Ro >1 Vm. It 
should also be noted that the steady-state clearance is always less than the 
intrinsic clearance, except when first order kinetics are operating. 
Now, from Eq. (31): 
g~l-  poz  V m  
CLi = lim ,-~,--I ~s - ........ (32) 
R-' .O g m  
where CLi is the intrinsic clearance, or the maximal ability of the liver to 
irreversibly remove drug by hepatic metabolism in the absence of flow 
limitations (3). 
By expanding the right-hand side of Eq. (31) and utilizing Eq. (32) we 
obtain: 
= CLi- - -~- -  Ro (33) Ctpoz X-q ss 
m 
poz  Equation (33) indicates that a plot of ~ssc~rv~ (i.e., R o / C l s s )  vs. dose rate 
Ro, will yield a straight line with intercept equal to the intrinsic clearance, 
CL~, and slope equal to -1~Kin.  Parameter estimates may be made with 
Eqs. (34) and (35). 
Km = 1 / [ S l o p e l  (34) 
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where the bars represent "absolute value of." 
Vm = K~CLi  (35) 
Equation (31) was first reported for the one-compartment open model 
by Sawchuk and Rector (36), but has been shown to be applicable to the 
two-compartment open model in this article. 
Equations (29) through (33) have been derived in this article when 
input to the liver is truly zero order. This can be accomplished in an animal 
by infusing the drug at a constant rate into the portal vein. It can be 
accomplished approximately in man by administering an aqueous solution 
of a drug in small increments to steady-state, or by giving repetitive doses 
first at a high dose rate then switching to a slower dose rate (37). However, 
Eqs. (29) through (33) often apply when oral input is not zero order and 
when Ro is replaced by Deo/~" and ,~ls,rP~ is replaced by the average steady- 
state concentration, ,--ls,,c~P~ defined as the area under the concentration-time 
curve at steady-state divided by the dosage interval z. An example of one 
such application recently is verapamil (38), but there are many others. Use 
of Eq. (33) will introduce some bias into estimates of CLi, V,,, and K,, since 
it is a linear transformation of a nonlinear equation. To obtain better 
estimates of  these parameters one should use Eq. (30) and either nonlinear 
least squares regression or a modification of Wilkinson's method (39). 
If one substitutes from Eq. (31) into Eq. (25) one obtains Eq. (36). 
ctVz _ Ro/ Q +  ,~poz (36) 
l s s  - -  ~J l s s  
Hence, if the rate R0 is the same intravenously and orally, then: 
['~ I V z  - -  g-'y p o z  h 
Q = R o / ( ~ , ~  ,~l,~J (37) 
Solving for Km in Eq. (33) gives Eq. (38). 
Ro 
K m -  (38) 
CLi - CLf~ 
Solving for V,, in Eq. (33) gives Eq. (39). 
Ro 
Vm = KmCL, -- - -  (39) 
C l -  p o z  
.t-, l s s 
I - - -  
CL~ 
Equations (38) and (39) were given formerly by Wagner (38). 
In applying Eqs. (38) and (39) one can give a single low oral dose so 
that kinetics are first order and make an estimate of CLi as the ratio of the 
dose to the total area under the concentration-time curve in the usual 
manner. 
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Bioavailability and Extraction Ratios 
Using the definition of bioavailability corresponding to input rate Ro, 
namely F,~, given under symbolism above, and using Eqs. (25, 30, 31) we 
obtain: 
Ro 4 KmRo 
p I V z  1 . ~  Q Vm-Ro Vm-Ro 
- - + l =  
F,s ".~ ls,re~ KmRo QKm 
V, , -  Ro 
Inverting both sides of Eq. (40) gives Eq. (41). 
1 Q 1 
Fss- i . " , f  p o z  ( ~ l  POZ ,-',-,l~s Q+ "~l,s Vm -Ro  
1 + - -  1 4  - -  
Q QKm 
Rearrangement of Eq. (41) gives Eq. (42). 
l - F , ,  V., 1 
Ro 
Fss QK, , ,  QKm 
C l~ p o z  . tJ  l s s  




Equation (42) indicates that a plot of 1 - Fs,/E~, vs. Ro will be a straight 
line with intercept equal to Vm/QKm (or CL~/Q) and a slope equal to 
-1/QKm. Thus an estimate of V,, is given by Eq. (43). 
Intercept 
Vm- iS lope  ] (43) 
To estimate the parameters Vm, Kin, and Q it is preferable to fit 4 or 
more F,s values corresponding to 4 or more different Ro values, by nonlinear 
least squares regression using Eq. (41). Equations (33,42) and (43) are 
useful to obtain preliminary estimates of the parameters. 
It follows from Eq. (41) that the intrinsic bioavailability, corresponding 
to blood flow Q, is given by Eq. (44). 
1 Q 
Fi= lim (F,~)= CLi Q+CLi (44) 
Ro~O 1 + - -  
O 
The steady-state extraction ratio, Es,, across the liver, is given by Eq. 
(45) in conventional symbolism and by Eq. (46) 
C,-Co co 
E,s - 1 - -  (45) 
c~ G 
in the symbolism of this article. 
84 Wagner, Szpunar, and Ferry 
Utilizing Eqs. (28), (37), and (41) one obtains: 
( ~  ~ T poz  ~ I V z  - -  f - ,  poz  
I '~L~Iss ~'~ Iss  ""  l s s  
Es~ = 1 - F , ~  = 1 Q +t'tp~ s~ Q +rrp~ ss ~'~l~IVZl ss (46) 
And, from Eq. (46) the intrinsic extraction ratio, corresponding to 
blood flow, Q, is: 
CL~ 
E~ = lim (E~) = -  (47) 
r ~o Q + CLi 
Analogously, from Eq. (25) we obtain Eq. (48), and 
c t l W =  Ro 1 1 (48) ~t"l ss ['~ I V z  - -  
1 ~ 1 Km 1 1 
b - -  q - - -  
Q V ~ - R o  Q r~tP~ 
the intrinsic hepatic clearance; corresponding to blood flow Q, is given by: 
r~rIV~ _ 1 1 QCLi 
CLH = QE~ = lim ~ , ~  - - (49) 
R ~O 1 K ~  1 1 Q +  CL~ 
Q V~ Q CL~ 
Equations (44), (45), (47), and (49) were originally reported by Rowland 
et al. (2) and Wilkinson and Shand (3). These equations are the limits of 
the nonlinear equations derived in this article; hence, the nonlinear 
equations are consistent with classical first order physiologic phar- 
macokinetics. This is emphasized by the equations in Table I. 
Effect o f  Protein Binding and Red  Cell Binding in Blood 
All the previous equations have been written in terms of total (bound + 
free) drug concentrations in whole blood, but may equally as well be written 
T poz  in terms of free (unbound) drug concentrations. In the latter case ,~lss  
and c,~ lvz . ~ ..'~rpozf ~c p T I V z f  ,~lss  are replaced oy J~t~Llss and Ju,--~ls~ , respectively, where fu is 
the fraction unbound in blood and the clearances are the corresponding 
clearances of free (unbound) drug. CLi would be replaced by fuCLY~, where 
CL f is the intrinsic clearance of unbound drug. Levy and Yacobi (40) 
experimentally showed that the total clearance of warfarin in rats was 
directly proportional to the free fraction, f~. This relationship is readily 
derived from 'the two mass balance Eqs. (50) and (51) and Eq. (49) as 
shown formerly (30). 
F~Opo = C L n ( A U C  O - ~ ) p o  (50) 
D , v  = C L n (  A U C  O-oO) ,v  (51) 
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Table I. Comparison of First-Order and Nonlinear Model Expressions 
Parameter Route First order model Nonlinear model 
Ro Ro Ro KmRo poz Steady-state c o n c n ,  o r a l  Clss C L  i v2ge 1 CPs ~z - poz CLlss V,,, - R o 
Vm- Ro 
Steady-state clearance oral CLi = V2ke~ CL p~ = -  
Kin 
c o n c h .  C l s s -  ~ - ~ i ]  C l s s -  O~-Q V m _ R o ]  Steady-state i.v. ,VZ_R ( I +  1 "~ wz R ( 1  + K,,, '~ 
1 zvz 1 
CLtss Q + CLi 1 1 CLlss 1 K,, Steady-state clearance i.v. wz_ QCL~ 
O CL, Q Vm-Ro 
Q 1 Q 
Bioavailability oral F~ = -  ~ - -  F~, 
Q + CL~ CL i Q + CLP~  
l + - -  
O 1 
V,,,-Ro 
1 - b - -  
QK~ 
Equation (49) may also be written as eq. (52). 
O_LcL~ 
C L .  = Q + f~ C L  f 
Equation (50) may also be written as Eq. (53) .  




C L u  
CLi - (54) 
Fi 
which is a fundamental  equation of classical physiological pharmacokinetics 
(3). 
Effect  o f  Tissue Binding 
As stated earlier, tissues may be attached to either compartments  # 1 
or # 2  by a pair of  first-order rate constants like k~2 and k21, and such tissues 
may bind the drug; such binding at steady-state would not change the 
kinetic situation described. However, the volumes, V~ and V2, would change 
since the tissues would hold some of the drug. The clever hydrodynamic 
analogue of  Tucker (32) has compartments  1 and 2 of  Scheme I as fluid 
compartments  with goldfish (the analogy to tissues) swimming in the fluids 
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in the two compartments. Nonlinear tissue binding could also be added to 
the basic model. 
Dependence of Oral Bioavailability on Liver Blood Flow 
It should be carefully noted that all the oral bioavailabilities, namely 
F~ and Fs~, are dependent upon liver blood flow, Q, even though the oral 
steady-state concentration and clearance are independent of liver blood flow. 
Urinary Excretion of Unchanged Drug 
If there were urinary excretion of unchanged drug according to first- 
order kinetics Schemes I and II would be modified by showing an exit rate 
constant with rate constant, ke, off of compartment #1. Thus, the renal 
clearance of unchanged drug would be CLR = Vl ke. This would modify Eq. 
t,-~l 1"~ I V z  (19) by the addition of a term, -,--,R,--,ss, on the right-hand side. The net 
effect is that Eqs. (21) through (25) would have Ro replaced by Ro-  
Cr  rtvz Both the intravenous and oral cases are covered in the Appendix. . t . ,R ,~ .  l s  s . 
DISCUSSION 
The models of Schemes I and II and obvious descendents, brought 
about by modification, appear to explain much of the clinical phar- 
macokinetic and physiologic observations made with first-pass drugs and 
reported in the literature. The senior author has surveyed the literature and 
believes most, if not all, first-pass drugs obey Michaelis-Menten elimination 
kinetics when given orally, and linear pharmacokinetics when administered 
intravenously. This is most likely the result of the difference in doses and 
the higher concentrations (as a result of both higher dose and lower volumes) 
when the drugs are given orally than when they are given intravenously. 
Pond and Tozer (13) did an excellent job of explaining this concentration 
difference with their Fig. 1. 
The most important equations derived in this article are Eqs. (25), (30), 
(33), (38), (39), (41), and (42) and Eqs. (62) and (69) of the Appendix. In 
applying the equations, measurement of whole blood drug concentrations 
are preferred, but plasma concentrations may also be measured (see under 
r and Q in Symbolism). To determine whether one or more of the equations 
apply the following are guidelines. On rectilinear graph paper plot the 
steady-state concentrations vs. dose rate. If the steady-state concentration 
increases more than proportionately with increase in dose rate then applica- 
bility of the equations is feasible. If the concentrations were measured after 
oral administration then plot Ro/CLPs 'z (i.e., ~rvo~.~ ,-,lss/vs. Ro according to Eq. 
(33) ; if the data appear linear then obtain the least squares line and apply 
Eqs. (34) and (35) to obtain preliminary estimates of V~ and Kin. Then use 
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these ini t ia l  es t imates  to fit the  da ta  by  non l inea r  least  squares  us ing Eq. 
(30) or  use Wi lk inson ' s  m e t h o d  (39) to ob ta in  final es t imates  o f  V,, and  
Kin. I f  s teady-s ta te  concen t ra t ions  are also ava i lab le  fo l lowing  in t ravenous  
in fus ion  at different  rates try fitting the da t a  by  non l inea r  least  squares  to 
Eq. (25) us ing as ini t ia l  es t imate  o f  Q the average  l iver  b l o o d  flow o f  
1.5 L / m i n  in man.  Since you need  at least  one  degree  o f  f r eedom,  fitting 
r~P~ Ro  points .  Fo r  to Eq. (30) requires  a m i n i m u m  of  three  pa i rs  o f  ~ l s s ,  











O08E RATE (R o) IN M~j/HOUR 
Fig. 1. Projected bioavailability of verapamil as a function 
of dose rate. Mean V,, Kin, and Q values of six subjects, 
obtained from the data of Freedman et al. (41), were Vm = 
536 mg/day = 21.33 mg/hr, Km= 103 ng/ml = 0.103 mg/L 
and Q = 1.15 L/min = 69 L/hr. Substitution of these values 
into Eq. (41) gave F,~ = 1/(1 + (22.33 - Ro)/7.107) from which 
the plot was prepared. 
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Equation (41) indicates that the steady-state bioavailability increases 
more than proportionately with increase in dose rate. When F~s is plotted 
vs. Ro on rectilinear graph paper the intercept on the ordinate scale is Fi 
(Eq. 44) then the plot curves upward and Fss ~ 1 as Ro ~ Vm. An example 
is shown in Fig. 1 for verapamil, where the values of Vm, Kin, and Q were 
estimated from the data of Freedman et al. (41). Linearity of a plot of 
(1-Fss) /F~ vs. Ro, based on Eq. (42) will indicate applicability of the 
nonlinear model. Using the Vm estimate obtained with Eq. (43), assuming 
Q= 1.5 L/min initially, then an initial estimate of K,, may be obtained 
from the intercept of the above plot. With these initial estimates the F~, Ro 
data may be fitted to Eq. (41) by nonlinear least squares, 
The model of Scheme II is readily modified by including first order 
metabolism parallel to Michaelis-Menten elimination. If there are two or 
more parallel Michaelis-Menten paths leading to two or more metabolites, 
then one often estimates pooled parameter values as discussed by Sedman 
and Wagner (42). Sometimes a parallel Michaelis-Menten and first order 
path also "pool" as shown by Wagner (43). This is simply the result of a 
lack of sufficient information in the concentration-time data. However, such 
pooled parameter estimates are still useful for making clinical phar- 
macokinetic predictions. 
An additional useful component may be built into a human or animal 
protocol. Concentrations can be continued to be measured after input has 
ceased so that fall-off data are collected. If applicable, such downslope 
concentration-time data may be fitted to the integrated form of the 
Michaelis-Menten equation via numerical integration of the Michaelis- 
Menten equation. This procedure provides estimates of K,~ and V~ = Vm/V2 
as performed by the senior author and his coworkers (44, 45), where the 
V,, is obtained from the steady-state data as indicated above. An estimate 
of V2 is then given by V 2 = Vrn / Vtrn. 
Future articles in the series will be concerned with single doses, evalu- 
ation of literature data according to the derived equations, and application 
of the model in toxicology and clinical pharmacokinetics and therapeutics. 
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APPENDIX 
Model modification when there is urinary excretion of unchanged drug 
according to first order kinetics is shown in Fig. 1A. 
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R 
o 
V 2 V m R o V 2 V m 
c I V z  ~ ~ poz  
2ss K m -C2ss K m / 
I~ c lw ~ > ] Iss 
I n t r a v e n o u s  Oral  
A d m i n i s t r a t i o n  A d m i n i s t r a t i o n  
Fig. lA. Modified nonlinear model whenthere i s  first-orderrenalexcretion of drug. 
Intravenous Administration 
Utilizing Eq. (8) and C L R  = V lke  the differetial equations are: 
l V z  
. { d C l ~ ' ~  - C L  r~Ivz t q : r l v z  rlvz~=0 (55) v, -Tv) : Ro - 2ss, 
I V z  IZ [ - ,  I V z  
. [ d C 2 , s \  , q : p l v z  r I w ~  , ,~ ,~2~  
v z ~ - ~ t ] = ' ~ ' - ~ ' ~ - ' ~ 2 ~ '  Kin+ r'w=0*--~2ss (56) 
From Eq. (55) one obtains: 
__ t . ~ t  t . ~ l V z  _ t . ) (  g -~ l Vz  __ g-~IVzh 
Ro "~'-R~,~, - ' r  "~2~ J (57) 
From Eq. (56) one obtains: 
1/" f ~  I V z  
#"~( f ~ I V z  f ~ I V z ' ~  9 m*"~2ss  
" ~ k ' ~  l s s  - -  " ~ 2 s s  ] Km + c~fvz (58) 
From Eq. (57) and (58) one obtains Eq. (59). 
"1] ~ IVz 
P F  f ' , l V z  v m ~ J 2 s s  
Ro - ".JL~R'~" lSS - -  K m  + ""~2ss c~W (59) 
c~Iw in Eq. (59) gives: Solving for ~z~ 
I V z  
r~1v~ Km[Ro - -  C L R C l s s  ] 
"~2,~ = _ - C 1Vz (60) 
V ~  [ R o  L R C I ~ ]  
Substituting for C~ w from Eq. (60) into Eq. (57) gives: 
C L ~ C  t~, ] _ r r  r ~Iv~ - r~r  ~xv~ Q K m [ R o  - xv~ 
Ro t-.a.~R~.~ l s  s - -  v , ~ - ,  l s  s 
C L R C l s s ]  
V,,, - [ R o  - , w  (61) 
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Solving for ,~l~Wz in Eq. (61) gives Eq. (62). 
t~ = R o -  C L R C  + 
I V z  
K m [  R o -  CLRC l ss ] 
-- C L  R C i ss ] Vm [ R o -  iVz 
(62) 
Oral Administration 
The differential equations are: 
/ dt'~poz\ 
[ ~ ' J l s s  - -  __[')[['~poz,~\~.~lss ~'~2ssJPP~ - -  C i -  [ -~poz  j -  --o 
p o z  . [ d C e s ~  v c~poz 
V2~T) :Ro+f~[g '~P~176  ' ~ 2 s s ]  " m ' ~ J 2 s s  
From Eq. (53) one obtains: 
__l '~ i"  ["~poz - -  i ~ (  l ~ p o z  [ ' ~ p o z ~  
~ '~J '~Rl '~ lss  - -  ~ .~k~"~ l s s  ~ ' ~ 2 s s ]  
Equations (64) and (65) yield: 
/'~1- t '~ P ~  Ro - ~...~L,R ~ I ss  - -  
Solving for ,-~2ssg'P~ in Eq. (66) gives: 
V , , ~ p o z  
""~2ss  
_ l _ l ' ~ p o z  
g m  - -  "~-'2ss 
~ p o z  





p o z  
r~poz K , , [ R o  - CLRC]~s] 
9 --2ss - . . . .  ~ (67) 
Vm - [ R o  - CLRC~ss]  
Substituting for ,.~2ssr~P~ from Eq. (67) into Eq. (65) gives: 
p o z  
_ r r  r p o z _  r~r~poz_ Q K m [ R o -  CLRC~s~] 
~ R ~ l s s  -- 'r - - - -  po - - - - -~  (68) 
Vm - [ R o  - C L R C I ~ ]  
Rearrangement of Eq. (68) gives Eq. (69). 
r~P~ = Q . Km[Ro- CLgCP~ (69) 
+ C L R / \  Vm - [ R o  - CLRC1~s]] 
Equation (30) indicates that in the absence of urinary excretion of 
unchanged drug the steady-state concentration after oral administration is 
independent of liver blood flow, Q. However, Eq. (69) indicates that when 
there is first-order elimination of unchanged drug (from compartment # 1 
of the model of Scheme II) then the steady-state concentration after oral 
administration is dependent upon liver blood flow, Q. 
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